公开(公告)号：US20220233561A1

公开(公告)日：2022-07-28

申请号：US17615479

申请日：2020-06-04

申请人： GLYCOM A/S

发明人： Bruce MCCONNELL ,  Louise Kristine VIGSNÆS

IPC分类号： A61K31/702 ,  A23L33/125

摘要： The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in, and a method for prophylactically reducing symptom severity and/or occurrence in a non-coeliac wheat and/or gluten sensitivity patient, and for reducing the severity and/or occurrence of non-gastrointestinal symptoms in the patient.

公开(公告)号：US20210000849A1

公开(公告)日：2021-01-07

申请号：US17026616

申请日：2020-09-21

申请人： GLYCOM A/S

发明人： Bruce MCCONNELL ,  Emma ELISON ,  Louise Kristine VIGSNÆS

IPC分类号： A61K31/702 ,  A23L33/00 ,  A23L33/15 ,  A61P25/22 ,  A61P25/24

摘要： A synthetic composition for use in treating or improving one or more emotion and/or mood disorders in a patient, characterised in that the composition contains an effective amount of one or more neutral human milk oligosaccharides, is disclosed.

公开(公告)号：US20220378809A1

公开(公告)日：2022-12-01

申请号：US17755956

申请日：2020-11-13

申请人： GLYCOM A/S

发明人： Louise Kristine VIGSNÆS ,  Bruce MCCONNELL

IPC分类号： A61K31/702 ,  A61K35/745 ,  A61K9/48 ,  A61K9/16 ,  A61P1/12

摘要： This invention relates to a method and composition for balancing the bile acid profile in the intestine of humans, particularly decreasing primary bile acids and/or increasing production of secondary bile acids.

公开(公告)号：US20210000848A1

公开(公告)日：2021-01-07

申请号：US17001118

申请日：2020-08-24

申请人： GLYCOM A/S

发明人： Louise Kristine VIGSNÆS ,  Bruce MCCONNELL

IPC分类号： A61K31/702 ,  A61P3/04 ,  A61P3/10 ,  A61P1/00 ,  A61K9/00

摘要： A human milk oligosaccharide (HMO) or a synthetic composition comprising said HMO, for use in increasing the abundance, particularly the relative abundance, of a Bifidobacterium of the B. adolescentis phylogenic group in the microbiota in the gastro-intestinal tract of a human, preferably a non-infant human. The HMO(s) and/or synthetic composition is useful in; increasing particularly the relative abundance of B. adolescentis and/or B. pseudocatenulatum; for treating or preventing in said non-infant human with type 2 diabetes and/or obesity; an enteropathogenic infection; impaired gut barrier function and/or; an inflammation related to gastro¬intestinal condition, preferably irritable bowel disease (IBD) or irritable bowel syndrome (IBS); as a nutritional composition. The HMO is a fucosylated neutral HMO, a non-fucosylated neutral HMO, or a mixture of a fucosylated and a non-fucosylated neutral HMO. The HMOs comprises 2′-fucosyllactose (preferred), 2′-fucosyllactose (preferred), 3-fucosyllactose, difucosyllactose (preferred), lacto-N-fucopentaose, fucosyl-lacto-N-hexaose, fucosyl-para-lacto-N-hexaose, lacto-N-tetraose (preferred), lacto-N-neotetraose (preferred), lacto-N-hexaose, lacto-N-neohexaose, para-lacto-N-hexaose and para-lacto-N-neohexaose.

公开(公告)号：US20180369260A1

公开(公告)日：2018-12-27

申请号：US15771189

申请日：2016-10-28

申请人： GLYCOM A/S

发明人： Bruce MCCONNELL ,  Emma ELISON ,  Louise Kristine VIGSNÆS

IPC分类号： A61K31/702 ,  A61P1/00 ,  A23L33/15 ,  A61P25/24 ,  A61P25/22

摘要： A synthetic composition for use in improving one or more co-morbid mental disorder symptoms of a patient with IBS, characterised in that the composition contains an effective amount of one or more neutral human milk oligosaccharides, is disclosed.

公开(公告)号：US20230014752A1

公开(公告)日：2023-01-19

申请号：US17934123

申请日：2022-09-21

申请人： GLYCOM A/S

发明人： Louise Kristine VIGSNÆS ,  Bruce MCCONNELL

IPC分类号： A61K31/702 ,  A23L33/21 ,  A23L33/00 ,  A61P1/00

摘要： The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in, and a method for the treatment of, secondary prevention of, and/or induction of tolerance to non-coeliac wheat and/or gluten sensitivity in a human.

公开(公告)号：US20220395520A1

公开(公告)日：2022-12-15

申请号：US17821282

申请日：2022-08-22

申请人： GLYCOM A/S

发明人： Nikolay KHANZHIN ,  Markus JONDELIUS HEDEROS ,  Louise Kristine VIGSNÆS ,  Bruce MCCONNELL

IPC分类号： A61K31/702 ,  C12P19/04 ,  C12P1/04 ,  C12N9/10 ,  A61K31/716 ,  A61P31/04 ,  A61K31/7016 ,  A61K31/7032 ,  C07H1/00

摘要： A mixture of human milk oligosaccharides that comprises or consists essentially of a) LNTri II, LNT, pLNH II and optionally lactose, or b) LNTri II, LNnT, pLNnH and optionally lactose, and is useful for preventing or treating viral or bacterial, intestinal and respiratory infections and for modulating the human gastrointestinal microbiota to increase Bifidobacterium abundance. A process for preparing the mixture and methods of crystallizing LNnT and LNT is also described.

公开(公告)号：US20190175631A1

公开(公告)日：2019-06-13

申请号：US16312506

申请日：2017-06-23

申请人： GLYCOM A/S

发明人： Nikolay KHANZHIN ,  Markus JONDELIUS HEDEROS ,  Louise Kristine VIGSNÆS ,  Bruce MCCONNELL

IPC分类号： A61K31/702 ,  A61K31/7032 ,  A61K31/7016 ,  A61P31/04 ,  C07H1/00

摘要： A mixture of human milk oligosaccharides that comprises or consists essentially of a) LNTri II, LNT, pLNH II and optionally lactose, or b) LNTri II, LNnT, pLNnH and optionally lactose, and is useful for preventing or treating viral or bacterial, intestinal and respiratory infections and for modulating the human gastrointestinal microbiota to increase Bifidobacterium abundance. A process for preparing the mixture and methods of crystallizing LNnT and LNT is also described.

公开(公告)号：US20180368460A1

公开(公告)日：2018-12-27

申请号：US16062598

申请日：2016-12-15

申请人： GLYCOM A/S

发明人： Bruce MCCONNELL ,  Louise Kristine VIGNÆS

IPC分类号： A23L33/00

摘要： A synthetic mixture of human milk oligosaccharides (HMOs) consisting essentially of lacto-N-neotetraose (LNnT), lacto-N-tetraose (LNT), 2′-fucosyllactose (2′FL), 3′-O-sialyllactose (3′-SL), 6′-O-sialyllactose (6′-SL) either difucosyllactose (DFL) or 3-fucosyllactose (3-FL), preferably DFL, and optionally lactose. Said synthetic composition is useful for: treating or preventing viral and/or bacterial infection in a non-infant human; modulating the microbiota of a non-infant human; and/or improving the cognitive function of a non-infant human and as a pharmaceutical or nutritional composition.

公开(公告)号：US20180185396A1

公开(公告)日：2018-07-05

申请号：US15759754

申请日：2016-09-14

申请人： GLYCOM A/S

发明人： Louise Kristine VIGSNÆS ,  Bruce MCCONNELL

IPC分类号： A61K31/702 ,  A61K9/00 ,  A61P1/00 ,  A61P3/04 ,  A61P3/10

CPC分类号： A61K31/702 ,  A61K9/0053 ,  A61P1/00 ,  A61P3/04 ,  A61P3/10

摘要： A human milk oligosaccharide (HMO) or a synthetic composition comprising said HMO, for use in increasing the abundance, particularly the relative abundance, of a Bifidobacterium of the B. adolescentis phylogenic group in the microbiota in the gastro-intestinal tract of a human, preferably a non-infant human. The HMO(s) and/or synthetic composition is useful in; increasing particularly the relative abundance of B. adolescentis and/or B. pseudocatenulatum; for treating or preventing in said non-infant human with type 2 diabetes and/or obesity; an enteropathogenic infection; impaired gut barrier function and/or; an inflammation related to gastro intestinal condition, preferably irritable bowel disease (IBD) or irritable bowel syndrome (IBS); as a nutritional composition. The HMO is a fucosylated neutral HMO, a non-fucosylated neutral HMO, or a mixture of a fucosylated and a non-fucosylated neutral HMO. The HMOs comprises 2′-fucosyllactose (preferred), 2′-fucosyllactose (preferred), 3-fucosyllactose, di-fucosyllactose (preferred), lacto-N-fucopentaose, fucosyl-lacto-N-hexaose, fucosyl-para-lacto-N-hexaose, lacto-N-tetraose (pre-ferrel), lacto-N-neotetraose (preferred), lacto-N-hexaose, lacto-N-neohexaose, para-lacto-N-hexaose and para-lacto-N-neohexaose.